Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27835658 | 1.00 | HTR2A (0.51) | HTR2AHTR2CTAAR1DPP4HTR1A | |
| SCHEMBL31599408 | 1.00 | HTR2A (0.51) | HTR2AHTR2CTAAR1DPP4HTR1A | |
| SCHEMBL31599440 | 0.85 | HTR2A (0.51) | HTR2AHTR2CTAAR1DPP4 | |
| SCHEMBL30681523 | 0.85 | HTR2A (0.51) | HTR2AHTR2CTAAR1DPP4 | |
| SCHEMBL13647178 | 0.85 | DPP4 (0.40) | HTR2AHTR2CTAAR1DPP4 | |
| SCHEMBL16986776 | 0.81 | ALOX15 (0.39) | HTR2AHTR2CDPP4 | |
| SCHEMBL3459241 | 0.81 | ALOX15 (0.39) | HTR2AHTR2CDPP4 | |
| SCHEMBL439656 | 0.81 | DPP4 (0.56) | HTR2AHTR2CDPP4 | |
| SCHEMBL441142 | 0.81 | DPP4 (0.56) | HTR2AHTR2CDPP4 | |
| SCHEMBL438798 | 0.79 | HTR2A (0.53) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | HTR2A 3742/4885HTR2C 2541/4885TAAR1 1120/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | HTR2A 3742/4885HTR2C 2541/4885TAAR1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.